Point72 Asset Management’s Cidara Therapeutics CDTX Stock Holding History

Point72 Asset Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-200,000	Closed	-$44.2M	–	3839
2025 Q4	$44.2M	Buy	+200,000	New	+$32.3M	0.05%	464

Point72 Asset Management's CDTX Position: Q1 2026 in Review

Point72 Asset Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 250,000 shares — an estimated $55.2M sold.

Point72 Asset Management first reported a position in CDTX in Q4 2021 and held it in 15 quarters. The position peaked at $151M in Q3 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Point72 Asset Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Point72 Asset Management sold 250,000 Cidara Therapeutics shares in Q1 2026, an estimated $55.2M.
Point72 Asset Management first reported a position in Cidara Therapeutics in Q4 2021 and held it in 15 quarters.
Point72 Asset Management's Cidara Therapeutics position peaked at $151M in Q3 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.